Biogen first-quarter profit jumps 71 percent as MS drug Tecfidera shines

(Reuters) - Biogen Inc reported a 71 percent rise in quarterly profit, driven by strong demand for its top-selling oral multiple sclerosis (MS) drug, Tecfidera.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.